Dashboard
Manage Tickers

NTLA


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

expert-outlook-intellia-therapeutics-through-the-eyes-of-7-analysts
Expert Outlook: Intellia Therapeutics Thro...
09/11/2024 12:00:24

stifel-maintains-buy-on-intellia-therapeutics-lowers-price-target-to-64
Stifel Maintains Buy on Intellia Therapeut...
09/11/2024 11:44:45

Stifel analyst Dae Gon Ha maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and lowers the price target from $80 to $64.

expert-ratings-for-intellia-therapeutics
Expert Ratings For Intellia Therapeutics
08/12/2024 16:01:14

jp-morgan-maintains-overweight-on-intellia-therapeutics-lowers-price-target-to-55
JP Morgan Maintains Overweight on Intellia...
08/12/2024 14:36:44

JP Morgan analyst Brian Cheng maintains Intellia Therapeutics (NASDAQ:NTLA) with a Overweight and lowers the price target fr...

rbc-capital-maintains-outperform-on-intellia-therapeutics-lowers-price-target-to-54
RBC Capital Maintains Outperform on Intell...
08/09/2024 19:43:27

RBC Capital analyst Luca Issi maintains Intellia Therapeutics (NASDAQ:NTLA) with a Outperform and lowers the price target fr...

intellia-therapeutics-cash-cash-equivalents-and-marketable-securities-were-9399m-as-of-june-30-2024-of-9399m-is-expected-to-fund-operations-into-late-2026
Intellia Therapeutics Cash, Cash Equivalen...
08/08/2024 11:39:29

intellia-therapeutics-q2-2024-gaap-eps-152-misses-124-estimate-sales-6957m-miss-19162m-estimate
Intellia Therapeutics Q2 2024 GAAP EPS $(1...
08/08/2024 11:37:41

intellia-therapeutics-receives-uk-mhra-authorization-to-initiate-initiate-phase-12-clinical-trial-of-ntla-3001-in-alpha-1-antitrypsin-deficiency
Intellia Therapeutics Receives UK MHRA Aut...
07/30/2024 11:41:49

intellia-therapeutics-receives-authorization-to-initiate-phase-12-clinical-trial-of-ntla-3001-for-treating-alpha-1-antitrypsin-deficiency
Intellia Therapeutics Receives Authorizati...
07/30/2024 11:41:11

bank-of-new-york-mellon-posts-upbeat-earnings-joins-archer-aviation-rivian-automotive-and-other-big-stocks-moving-higher-on-friday
Bank of New York Mellon Posts Upbeat Earni...
07/12/2024 14:27:17

cathie-woods-ark-invest-dumps-another-325m-worth-of-tesla-shares-amid-searing-q2-deliveries-rally
Cathie Wood's Ark Invest Dumps Another $3....
07/04/2024 01:52:52

cathie-woods-ark-invest-sells-tesla-shares-worth-145m-amid-rally-driven-by-q2-delivery-numbers-picks-up-palantir-shares-again-today
Cathie Wood's Ark Invest Sells Tesla Share...
07/03/2024 02:26:04

canaccord-genuity-maintains-buy-on-intellia-therapeutics-maintains-73-price-target
Canaccord Genuity Maintains Buy on Intelli...
06/27/2024 13:38:05

Canaccord Genuity analyst Whitney Ijem maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and maintains $73 price target.

cathie-woods-ark-invest-acquires-73m-worth-of-shares-in-this-promising-netflix-competitor-sells-off-coinbase-stock-amid-bitcoin-slump
Cathie Wood's Ark Invest Acquires $7.3M Wo...
06/27/2024 03:33:17

On Wednesday, Cathie Wood-led Ark Invest made significant trades in Roku Inc (NASDAQ:ROKU) and Coinbase Global Inc (NASDAQ:COIN...

intellia-therapeutics-named-edward-dulac-of-fate-therapeutics-as-cfo-effective-july-22-succeeding-glenn-goddard
Intellia Therapeutics Named Edward Dulac O...
06/26/2024 11:32:24

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine wi...

Core News & Articles
Intellia Therapeutics Presents Data On Red...
06/25/2024 19:32:54

First-ever clinical data demonstrating redosing with an investigational in vivo CRISPR-based therapyFollow-on dosing with a 55 ...

cantor-fitzgerald-reiterates-overweight-on-intellia-therapeutics-maintains-65-price-target
Cantor Fitzgerald Reiterates Overweight on...
06/24/2024 18:30:10

Cantor Fitzgerald analyst Rick Bienkowski reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Overweight and maintains $65...

unveiling-6-analyst-insights-on-intellia-therapeutics
Unveiling 6 Analyst Insights On Intellia T...
06/24/2024 18:01:29

truist-securities-maintains-buy-on-intellia-therapeutics-maintains-120-price-target
Truist Securities Maintains Buy on Intelli...
06/24/2024 17:34:40

Truist Securities analyst Joon Lee maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and maintains $120 price target.

rxo-alnylam-pharmaceuticals-and-other-big-stocks-moving-lower-in-mondays-pre-market-session
RXO, Alnylam Pharmaceuticals And Other Big...
06/24/2024 11:54:53

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION